Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins.
about
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNRInfectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexesGeneration of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vectorEvaluating Replication-Defective Vesicular Stomatitis Virus as a Vaccine VehicleHepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particlesReplication-Competent Recombinant Vesicular Stomatitis Virus Encoding Hepatitis C Virus Envelope ProteinsStudying Hepatitis C Virus: Making the Best of a Bad VirusIdentification of a Broadly Cross-Reacting and Neutralizing Human Monoclonal Antibody Directed against the Hepatitis C Virus E2 ProteinMutagenesis of the fusion peptide-like domain of hepatitis C virus E1 glycoprotein: involvement in cell fusion and virus entryIn vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopesCD81 is required for hepatitis C virus glycoprotein-mediated viral infectionRecombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge.Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus.Nonsegmented negative-strand viruses as vaccine vectors.Mechanisms of hepatitis C virus infection.Neutralizing antibodies in hepatitis C virus infection.Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein boosterNew therapeutic opportunities for hepatitis C based on small RNA.Recent contributions of in vitro models to our understanding of hepatitis C virus life cycle.The hypervariable region 1 of the E2 glycoprotein of hepatitis C virus binds to glycosaminoglycans, but this binding does not lead to infection in a pseudotype system."Marker of Self" CD47 on lentiviral vectors decreases macrophage-mediated clearance and increases delivery to SIRPA-expressing lung carcinoma tumorsHeat shock protein 70 enhances mucosal immunity against human norovirus when coexpressed from a vesicular stomatitis virus vector.Virus-like particle-based vaccines against hepatitis C virus infection.Lassa-vesicular stomatitis chimeric virus safely destroys brain tumorsTandem repeats of lactoferrin-derived anti-hepatitis C virus peptide enhance antiviral activity in cultured human hepatocytes.Expression of unmodified hepatitis C virus envelope glycoprotein-coding sequences leads to cryptic intron excision and cell surface expression of E1/E2 heterodimers comprising full-length and partially deleted E1Characterization of functional hepatitis C virus envelope glycoproteins.Generation of infectious HCV pseudo typed particles and its utilization for studying the role of CD81 & SRBI receptors in HCV infection.Animal Models to Study Hepatitis C Virus Infection.Technical considerations for the generation of novel pseudotyped viruses
P2860
Q24551041-38347916-BEE8-417D-9538-081833A4A69BQ24673768-7DA2FFB0-6389-4DAF-A789-E306575C23DDQ27472940-634F70FF-FE31-4127-AD0B-32E912A985BAQ27473287-D96CFCA0-0FE3-457F-91C8-861DCBCD44D0Q27477687-94A0399C-F3EE-4733-AD63-0015AED408B7Q27481021-6964BE09-D358-4C2D-96BF-70FA52BF9E34Q27481034-FD595E0A-E716-4475-A60D-A154FAA2E64AQ27485318-74CB5E1D-02C5-47C7-A153-4DC239A9E1EBQ27489898-09D7A45E-5620-4AB6-9033-83E228688EAAQ27491029-091FFA51-2550-4055-A83D-D3C6F28848CEQ29619745-0AE7B352-17E6-40E5-8A19-079E110DB1DAQ34647625-2FA27F0D-F91C-42BE-B423-15D6D493B208Q34742846-0E226315-A44B-470E-9158-391276863329Q35139219-269F361B-417D-4E6A-801F-44AE6ABF497AQ35669529-864C62AB-1036-4EF3-B901-2FC5AE1234F9Q36179699-FA1A44F6-C863-479E-BEBE-DF5389D1A368Q36363203-74E2E4AB-F7E8-452C-AA3B-BE08182335A6Q36921336-CDE4863B-3A65-4443-831A-171B73691099Q36933791-85292DFA-5421-4691-BC83-2F1EDA94A3FFQ37422843-72E2DFC7-F177-40D0-BB4C-085D746FBFFBQ37490583-767C135C-0C83-4AED-8B8B-39788DA2EB36Q37713979-525A3D59-66D9-4A22-8E96-25A6712C5486Q38081966-65EBE885-7D22-443C-9B72-E43747B36A02Q38886667-59C525C4-A193-4ACB-A9C1-44F0649F29DBQ40181096-3D2FB109-6656-440D-A254-37EFAE1FD976Q40344741-87692828-E32F-4177-8549-67E86937611DQ40539381-4BFD5B6A-B374-49B5-9E91-3F2911370605Q42227908-A3A698C8-24E0-4C73-B3BA-A3E18426E258Q54988623-56F5C826-FBCA-4533-97E1-BE38B00BB75FQ57275154-81510590-BC33-44B7-B222-EEC8E19CEECB
P2860
Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Characterization of Vesicular ...... epatitis C Virus Glycoproteins
@nl
Characterization of vesicular ...... patitis C virus glycoproteins.
@ast
Characterization of vesicular ...... patitis C virus glycoproteins.
@en
type
label
Characterization of Vesicular ...... epatitis C Virus Glycoproteins
@nl
Characterization of vesicular ...... patitis C virus glycoproteins.
@ast
Characterization of vesicular ...... patitis C virus glycoproteins.
@en
prefLabel
Characterization of Vesicular ...... epatitis C Virus Glycoproteins
@nl
Characterization of vesicular ...... patitis C virus glycoproteins.
@ast
Characterization of vesicular ...... patitis C virus glycoproteins.
@en
P2093
P2860
P1433
P1476
Characterization of vesicular ...... patitis C virus glycoproteins.
@en
P2093
Charles M Rice
John K Rose
Keril J Blight
Linda Buonocore
P2860
P304
P356
10.1128/JVI.76.14.6865-6872.2002
P577
2002-07-01T00:00:00Z